Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2016

01-04-2016 | Research Paper

Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer

Authors: Maija P. Valta, Hongjuan Zhao, Matthias Saar, Johanna Tuomela, Rosalie Nolley, Johannes Linxweiler, Jouko Sandholm, Jaakko Lehtimäki, Pirkko Härkönen, Ilsa Coleman, Peter S. Nelson, Eva Corey, Donna M. Peehl

Published in: Clinical & Experimental Metastasis | Issue 4/2016

Login to get access

Abstract

LuCaP serially transplantable patient-derived xenografts (PDXs) are valuable preclinical models of locally advanced or metastatic prostate cancer. Using spheroid culture methodology, we recently established cell lines from several LuCaP PDXs. Here, we characterized in depth the features of xenografts derived from LuCaP 136 spheroid cultures and found faithful retention of the phenotype of the original PDX. In vitro culture enabled luciferase transfection into LuCaP 136 spheroids, facilitating in vivo imaging. We showed that LuCaP 136 spheroids formed intratibial, orthotopic, and subcutaneous tumors when re-introduced into mice. Intratibial tumors responded to castration and were highly osteosclerotic. LuCaP 136 is a realistic in vitro–in vivo preclinical model of a subtype of bone metastatic prostate cancer.
Literature
1.
2.
Groot MT et al (2003) Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 43(3):226–232CrossRefPubMed
3.
Lange PH, Vessella RL (1998) Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17(4):331–336CrossRefPubMed
4.
Parker C et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223CrossRefPubMed
5.
Mohler JL et al (2014) Prostate cancer, version 2.2014. J Natl Compr Canc Netw 12(5):686–718PubMed
6.
Crawford ED et al (2015) Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol 194(6):1537–1547CrossRefPubMed
7.
Ocana A et al (2011) Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol 8(4):200–209CrossRef
8.
Sausville EA, Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66(7):3351–3354 (discussion 4) CrossRefPubMed
9.
Sobel RE, Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol 173(2):342–359CrossRefPubMed
10.
Najy AJ et al (2012) Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate 72(12):1328–1338CrossRefPubMedPubMedCentral
11.
Valta MP et al (2008) FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 123(1):22–31CrossRefPubMed
12.
Bonfil RD et al (2007) Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 170(6):2100–2111CrossRefPubMedPubMedCentral
13.
van Weerden WM, Bangma C, de Wit R (2009) Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer 100(1):13–18CrossRefPubMedPubMedCentral
14.
15.
16.
Saar M et al (2014) Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett 351(2):272–280CrossRefPubMedPubMedCentral
17.
Ibrahim L, Wright EA (1983) Effect of castration and testosterone propionate on mouse vibrissae. Br J Dermatol 108(3):321–326CrossRefPubMed
18.
Saar M et al (2012) Experimental orthotopic prostate tumor in nude mice: techniques for local cell inoculation and three-dimensional ultrasound monitoring. Urol Oncol 30(3):330–338CrossRefPubMed
19.
Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675CrossRefPubMed
20.
Kumar A et al (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 108(41):17087–17092CrossRefPubMedPubMedCentral
21.
Wettenhall JM, Smyth GK (2004) limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20(18):3705–3706CrossRefPubMed
22.
Leek JT et al (2012) The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6):882–883CrossRefPubMedPubMedCentral
23.
Leeming DJ et al (2011) Serum N-terminal propeptide of collagen type i is associated with the number of bone metastases in breast and prostate cancer and correlates to other bone related markers. Biomark Cancer 3:15–23CrossRefPubMedPubMedCentral
24.
Edwards JR, Mundy GR (2011) Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 7(4):235–243CrossRefPubMed
25.
Zhang X et al (2015) Amplification and protein expression of androgen receptor gene in prostate cancer cells: fluorescence hybridization analysis. Oncol Lett 9(6):2617–2622PubMedPubMedCentral
26.
27.
Adley BP, Yang XJ (2006) Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol 28(1):1–13PubMed
28.
29.
Ganguly SS, Li X, Miranti CK (2014) The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol 4:364CrossRefPubMedPubMedCentral
30.
Nemeth JA et al (1999) Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59(8):1987–1993PubMed
31.
Graham TJ et al (2014) Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst 106(4):dju033CrossRefPubMed
32.
Yang J et al (2001) Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652–5659PubMed
33.
Hagberg Thulin M et al (2014) Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin Exp Metastasis 31(3):269–283CrossRefPubMedPubMedCentral
34.
Li ZG et al (2008) Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Investig 118(8):2697–2710CrossRefPubMedPubMedCentral
35.
Roychowdhury S et al (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111):111ra21CrossRef
36.
37.
Brennecke P et al (2014) CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice. Clin Exp Metastasis 31(3):339–349CrossRefPubMedPubMedCentral
38.
Drake CG (2014) Visceral metastases and prostate cancer treatment: ‘die hard’, ‘tough neighborhoods’, or ‘evil humors’? Oncology (Williston Park) 28(11):974–980
39.
Akfirat C et al (2013) Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol 230(3):291–297CrossRefPubMedPubMedCentral
40.
Morrissey C et al (2010) Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 70(16):1799–1808PubMedPubMedCentral
41.
Brubaker KD et al (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6:15CrossRefPubMedPubMedCentral
42.
Michiel Sedelaar JP, Dalrymple SS, Isaacs JT (2013) Of mice and men–warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate 73(12):1316–1325CrossRefPubMed
43.
Gonzalez-Billalabeitia E et al (2014) Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 4(8):896–904CrossRefPubMedPubMedCentral
44.
Semenas J et al (2014) The role of PI3K/AKT-related PIP5K1alpha and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci USA 111(35):E3689–E3698CrossRefPubMedPubMedCentral
Metadata
Title
Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer
Authors
Maija P. Valta
Hongjuan Zhao
Matthias Saar
Johanna Tuomela
Rosalie Nolley
Johannes Linxweiler
Jouko Sandholm
Jaakko Lehtimäki
Pirkko Härkönen
Ilsa Coleman
Peter S. Nelson
Eva Corey
Donna M. Peehl
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2016
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9781-2

Other articles of this Issue 4/2016

Clinical & Experimental Metastasis 4/2016 Go to the issue

Research Paper

Metformin may protect nondiabetic breast cancer women from metastasis

Research Paper

Characterization of passive permeability at the blood–tumor barrier in five preclinical models of brain metastases of breast cancer

Research Paper

β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases

Research Paper

Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Research Paper

Repositioning “old” drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion

Research Paper

MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits